« Return to News | Drug Sponsors

Merck continues plans to cut jobs

Friday, July 15, 2011 10:07 AM

Last year, Merck disclosed plans to save up to $3.5 billion by closing numerous research sites and manufacturing plants and eliminate roughly 15,000 jobs by 2012, or roughly 10% of the total headcount including the thousands of employees who were part of the 2009 acquisition of Schering-Plough. Before that deal, Merck employed about 53,000 people, reported Pharmalot.

By March, Merck had managed to get headcount down to 93,000, which means another 8,000 or so jobs must still go. Sources say the layoff process is expected to accelerate in early August, as the drug maker continues its restructuring plan and looks for additional ways to save money.

That more pink slips will be handed out is hardly surprising, given that Merck telegraphed the cuts a year ago. Numerous departments have been winnowed in recent months, particularly the Merck Research Laboratories, which once led the industry in new discoveries but now struggles to replenish the pipeline.

Merck execs are interested in bringing the headcount down further, sources say, and are continuing to review more operations, including reducing the scale of the research facility that opened in Boston seven years ago. A Merck spokesman, however, declined to comment on any upcoming moves.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.